SRPT News

Latest breaking news and updates for SRPT stock.

Track all markets on TradingView

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during...

Are there comparable biotech class action cases, and what impact did they have on their companies' valuations and investor sentiment? How might the filing influence SRPT's short‑term stock price volatility and trading volume? What is the potential financial exposure and settlement risk for SRPT arising from this securities class action?
Lawsuits
2 days ago
Read more prnewswire

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarep...

Are there broader implications for Sarepta’s pipeline financing or partnership agreements due to the litigation risk? What is the expected timeline for resolution or settlement, and could it impact upcoming earnings releases or guidance? How might this securities fraud lawsuit affect SRPT’s short‑term stock volatility and price direction?
Lawsuits
2 days ago
Read more prnewswire

SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Ther...

Should we consider adjusting position sizing or hedging strategies in response to the increased legal risk? What is the potential effect of this legal action on SRPT's valuation multiples relative to its peers? How could the lawsuit affect SRPT's stock liquidity and bid‑ask spreads during the litigation period?
Lawsuits
5 days ago
Read more businesswire

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLAS...

How does this lawsuit compare to legal risks faced by other biotech companies in similar situations? Will the lawsuit affect ongoing or upcoming clinical trial results or regulatory approvals for Sarepta's products? How might this lawsuit impact the company’s ability to raise capital or its credit facilities?
Lawsuits
5 days ago
Read more prnewswire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acqui...

How are institutional investors and major shareholders reacting to the news? What is the expected timeline for the investigation and any potential court filings? Could this litigation affect the company's ability to raise capital or its credit facilities?
Lawsuits
6 days ago
Read more prnewswire

Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during...

What are the potential short‑term and long‑term impacts on SRPT’s valuation and investor sentiment? Will this legal matter affect any upcoming regulatory approvals or collaborations? What impact could the lawsuit have on the company's ongoing clinical trials and product pipeline?
Lawsuits
6 days ago
Read more prnewswire

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common ...

What are the broader market implications for the rare‑disease and siRNA therapeutic space following this partnership update? How might this news influence analyst ratings or target price revisions for SRPT in the near term? Are there any regulatory or tax considerations tied to the privately negotiated block trade that could impact net proceeds?
Mergers
7 days ago
Read more businesswire

SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during...

How does the market's reaction to this news compare to reactions to other recent legal actions in the sector? Is there any disclosed information about the alleged misconduct or the specific claims that could impact the company's reputation or product development? Will the lawsuit affect Sarepta's ability to secure future financing, partnerships, or FDA approvals for its pipeline?
Lawsuits
9 days ago
Read more prnewswire